366 related articles for article (PubMed ID: 30089596)
1. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Suh CH; Park HS; Kim KW; Pyo J; Hatabu H; Nishino M
Lung Cancer; 2018 Sep; 123():60-69. PubMed ID: 30089596
[TBL] [Abstract][Full Text] [Related]
2. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
Suh CH; Kim KW; Pyo J; Hatabu H; Nishino M
Lung Cancer; 2019 Jun; 132():79-86. PubMed ID: 31097098
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer.
Xu K; Liang J; Zhang T; Zhou Z; Chen D; Feng Q; Xiao Z; Hui Z; Lu J; Wang X; Deng L; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
Thorac Cancer; 2021 Mar; 12(6):814-823. PubMed ID: 33501781
[TBL] [Abstract][Full Text] [Related]
4. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
Tang C; Li X; Guo W; Li J; Qin H; Wang W; Qu L; An J; Gao H; Liu X
Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):345-52. PubMed ID: 23866664
[TBL] [Abstract][Full Text] [Related]
5. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
9. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Watanabe S; Tanaka J; Ota T; Kondo R; Tanaka H; Kagamu H; Ichikawa K; Koshio J; Baba J; Miyabayashi T; Narita I; Yoshizawa H
BMC Cancer; 2011 Jan; 11():1. PubMed ID: 21194487
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
11. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
12. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
[TBL] [Abstract][Full Text] [Related]
13. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
15. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
16. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.
Chiang CL; Chen YW; Wu MH; Huang HC; Tsai CM; Chiu CH
J Chin Med Assoc; 2016 May; 79(5):248-55. PubMed ID: 27036494
[TBL] [Abstract][Full Text] [Related]
17. Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Xu R; Zhu J
Lung Cancer; 2019 Jan; 127():167. PubMed ID: 30292401
[No Abstract] [Full Text] [Related]
18. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
19. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis.
Qie W; Zhao Q; Yang L; Zou B; Duan Y; Yao Y; Wang L
Cancer Med; 2023 Jul; 12(13):13873-13884. PubMed ID: 37017467
[TBL] [Abstract][Full Text] [Related]
20. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]